Spero Therapeutics Inc

NASDAQ:SPRO   4:00:00 PM EDT
1.92
+0.01 (+0.52%)
7:59:02 PM EDT: $1.93 +0.01 (+0.52%)
Earnings Announcements

Spero Therapeutics Announces Third Quarter 2022 Operating Results

Published: 11/14/2022 21:46 GMT
Spero Therapeutics Inc (SPRO) - Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update.
Spero Therapeutics Inc- Reported a Net Loss for Q3 Ended September 30, 2022, of $11.7 Million Or $.
33 per Common Share.
Spero Therapeutics Inc- As of September 30, 2022, Spero Had Cash, Cash Equivalents, and Marketable Securities of $50.4 Million.
Revenue is expected to be $23 Million
Adjusted EPS is expected to be $0.04

Next Quarter Revenue Guidance is expected to be $2.1 Million
Next Quarter EPS Guidance is expected to be -$0.34

More details on our Analysts Page.